Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients
Apr 3, 2017Follicular lymphoma is an indolent yet incurable lymphoma characterized by a relapsingremitting course with initial responses to standard therapies, invariably followed by shorter disease free intervals. In recent years, significant treatment improve...
Clinical Studies - Apr 3, 2017 - Sep 30, 2020
Automatically Closed
Project leader: Hitz Felicitas
SAKK 41/16: Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal ca cer. A multicenter phase Ib trial (RECAP)
Mar 7, 2017Despite treatment of locally advanced rectal cancer re-lapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS). Recent studies with...
Clinical Studies - Mar 7, 2017 - Jul 31, 2019
Automatically Closed
Project leader: Jörger Markus
Amyloidosis Registry
Jan 1, 2017
Clinical Studies - Jan 1, 2017 - Dec 31, 2030
Ongoing
Project leader: Hitz Felicitas
Members: Steiner Marianne
SAKK 24/14: Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial
Nov 7, 2016Advanced triple negative breast cancer (TNBC) is a highly chemosensitive disease displaying a dismal short-term prognosis with more than three quarters of patients in pro-gression 12 months after the initiation of conventional chemotherapy. Approxima...
Clinical Studies - Nov 7, 2016 - May 31, 2023
Automatically Closed
Project leader: Weder Patrik
HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen
Nov 1, 2016Proteasominhibitor-Resistenz ist ein wichtiger unmet clinical need beim Multiplen Myelom (MM). Die Aktivität von next generation therapy (Daratumumab, Carfilzomib, Pomalidomid) ist hier bei ca. 30 % Partialremissionen (PR). Wir haben in vitro durch...
Fundamental Research - Nov 1, 2016 - Oct 31, 2018
Automatically Closed
Project leader: Driessen Christoph
Members: Kraus Marianne, Bader Juergen, Besse Lenka, Besse Andrej
SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the to erability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients
Oct 27, 2016This is a prospective, open label, multicenter study that is conducted in the frame of a masterprotocol with multiple parallel randomized phase II arms. The scheme of this design consists of one arm with the standard treatment for AML (the 10-day dec...
Clinical Studies - Oct 27, 2016 - Jul 31, 2018
Automatically Closed
Project leader: Fehr Martin
CA209-577: A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 577)
Oct 21, 2016CA209577 is a phase 3, randomized, double-blind, placebo controlled study of adjuvant nivolumab in subjects with resected esophageal cancer (EC), or gastroesophageal junction (GEJ) cancer who have received chemoradiother-apy(CRT) followed by surgery....
Clinical Studies - Oct 21, 2016 - Nov 30, 2017
Automatically Closed
Project leader: Weisshaupt Christian
PhenoTox: Hunting the missing heritability of early-onset fluoropyrimdine-related toxicity in cancer patients: an observational multi-center study
Oct 4, 2016In cancer patients receiving fluoropyrimidine-based chemo-therapy, there is extensive inter-individual variability in plasma drug concentrations and the severity of chemo-therapy-related toxicity. A strong association has been shown for plasma concen...
Clinical Studies - Oct 4, 2016 - Feb 27, 2024
Completed
Project leader: Jörger Markus
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451
Sep 7, 2016This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy. Approximately 810...
Clinical Studies - Sep 7, 2016 - Nov 30, 2020
Automatically Closed
Project leader: Früh Martin
An open-label Phase 1/2a study of BAL101553 adminis-tered as 48-hour intravenous infusions in adult patients with advanced solid tumors
Aug 19, 2016The primary objectives of this study are to determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of BAL101553, administered as an intravenous (IV) infusion over 48 hours on study Days 1, 8 and 15 of a 28-day...
Clinical Studies - Aug 19, 2016 - Jan 31, 2018
Automatically Closed
Project leader: Jörger Markus
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) / MK-3475-199 Pembro Prostata
Jul 27, 2016This is a nonrandomized, multinational, open-label trial of pembrolizumab (MK-3475) in subjects with metastatic cas-tration-resistant prostate cancer (mCRPC) previously treated with docetaxel-based chemotherapy. The trial will be conducted in conform...
Clinical Studies - Jul 27, 2016 - Jun 30, 2019
Automatically Closed
Project leader: Omlin Aurelius
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti PD-1 Monoclonal Anti-body) in Advanced Solid Tumors
Jul 21, 2016This is a Phase 1/2a, open-label study of BMS-986156 administered as a single agent and in combination with nivolumab in subjects with advanced solid tumors. The study will be conducted in 4 parts. Parts A and B will consist of dose escalation with B...
Clinical Studies - Jul 21, 2016 - Sep 30, 2017
Automatically Closed
Project leader: Jörger Markus
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)
Jul 15, 2016
Clinical Studies - Jul 15, 2016 - Oct 15, 2019
Automatically Closed
Project leader: Flatz Lukas
Members: Diem Stefan
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA (Abi-RE)
Jun 12, 2016Clinical Trial with an IMP, risk category B according to HRA. Abiraterone acetate (AA) is a standard treatment option both in chemotherapy naïve and docetaxel pre-treated men with metastatic castrate-resistant prostate cancer (CRPC). With the approva...
Clinical Studies - Jun 12, 2016 - Dec 31, 2017
Automatically Closed
Project leader: Omlin Aurelius
SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
Jun 3, 2016GRAALL-2014 follows the GRAALL-2003 and 2005 trials. The GRAALL-2014 trial is subdivided in three sub-studies: GRAALL-2014/B, GRAALL-2014/T and GRAAPH-2014respectively for patients with B-lineage Ph-negative ALL, T-lineage ALL or Ph+ ALL. France, S...
Clinical Studies - Jun 3, 2016 - May 31, 2026
Ongoing
Project leader: Silzle Tobias
Members: Quinter Janine
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
May 27, 2016Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of up to 42 days, eligible subjects can be randomized to either pembrolizumab (experimental...
Clinical Studies - May 27, 2016 - Nov 30, 2020
Automatically Closed
Project leader: Weisshaupt Christian
SAKK 08/14 Investigation of Metformin in patients with castration resistant Prostate Cancer in combination with Enzalu-tamide vs. Enzalutamide alone (IMPROVE TRIAL)
May 20, 2016The current standard of care for patients with metastatic castration resistant prostate cancer (mCRPC) and dis-ease progression is either treatment with abiraterone acetate and prednisone in asymptomatic or mildly symp-tomatic patients without viscer...
Clinical Studies - May 20, 2016 - Jul 31, 2026
Ongoing
Project leader: Rothermundt Christian
Klinische Phase-I-Studie zur Beurteilung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von EDO-S101, einem First-in-Class alkylierenden HDA-Ci-Fusionsmolekül, bei rezidivierenden/refraktären häma-tologischen Malignitäten
May 4, 2016Es handelt sich um eine zweistufige Phase-I-Studie. Stufe 1 der Studie dient der Bestimmung der MTD, der Identifika-tion der empfohlenen Stufe-II-Dosierung sowie der Ermitt-lung der optimalen Infusionsdauer. Stufe 2 dient der Bestä-tigung der Sicherh...
Clinical Studies - May 4, 2016 - Jan 1, 2018
Automatically Closed
Project leader: Driessen Christoph
A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin Paclitaxel with or without bevacizumab compared with carboplatin Paclitaxel bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer
Apr 14, 2016MPDL3280A ist ein humaner monoklonaler Antikörper der Immunglobulin (Ig)-Klasse G1 und wird in den Ovarialzellen des chinesischen Hamsters produziert. MPDL3280A wird als mögliche Therapie gegen solide Tumore und hämatologische Malignitäten in Mensche...
Clinical Studies - Apr 14, 2016 - Apr 14, 2020
Automatically Closed
Project leader: Früh Martin
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Mar 30, 2016Primary/co-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or with-out standard adjuvant chemotherapy for stage IB (T ≥ 4 cm) -II-IIIA NSCLC patien...
Clinical Studies - Mar 30, 2016 - Mar 30, 2020
Automatically Closed
Project leader: Früh Martin